Outlook Therapeutics names new SVP, clinical development

Outlook Therapeutics Inc., a clinical-stage biopharmaceutial company based in Cranbury, announced it has named Jennifer M. Kissner to the role of senior vice president, clinical development.

Kissner, who has extensive experience in therapeutic product development, most recently served as vice president, clinical development at Clearside Biomedical. Previously, she was director, clinical development at Acucela and held roles of increasing responsibility in retina development at Alcon.

“We would like to extend a warm welcome to Jennifer and are excited that she has joined the Outlook team,” Terry Dagnon, chief operating officer at Outlook Therapeutics, said. “Dr. Kissner’s extensive clinical development expertise, specializing in wet AMD and other retina diseases, will be an important asset to Outlook Therapeutics as we continue to advance the ONS-5010 program.”

The company also announced Kenneth M. Bahrt, chief medical officer, has left the company to pursue other opportunities. Outlook said it does not intent to replace the role.

“On behalf of the entire Outlook team, I would like to thank Dr. Bahrt for his valuable contributions to the Company for the past four years and wish him the best in his future endeavors,” Lawrence Kenyon, CEO, president and chief financial officer, Outlook Therapeutics, said. “These organizational changes reflect the continued evolution of Outlook Therapeutics as part of our strategy to focus on retinal diseases.”